ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Inclusion Criteria:

• Participant weighs ≥ 30 kg

• Planned non-emergent sternotomy with CPB procedure for the following surgeries:

• Multi-vessel CABG

• Valve replacement or repair; ascending aorta surgery permitted if combined withaortic valve replacement/repair

• Combined CABG and valve surgery; inclusion of single-vessel CABG when combined withvalve replacement/repair is permitted

• Known CKD for at least 90 days (CKD Stage 3A, 3B, or 4)

Exclusion Criteria:

• Emergency or salvage cardiac surgery is expected at screening or randomization, asassessed by the investigator.

• Single-vessel CABG without valve surgery is planned.

• Off-pump surgery is planned (eg, surgery without CPB).

• Recipient of a solid organ or bone marrow transplantation.

• Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump,extracorporeal membrane oxygenation, or left ventricular assist device within 72hours of randomization.

• Active systemic bacterial, viral, or fungal infection within 14 days prior torandomization.

• History of unexplained, recurrent infection.

• Any use of KRT or presence of AKI within 30 days of randomization

• Use of any complement inhibitors, or plasmapheresis or plasma exchange within theyear prior to Screening, or planned use during the course of the study.

• Participant is not willing to be vaccinated against N meningitidis or is unwillingto receive prophylactic treatment with appropriate antibiotics , if needed

• History of or unresolved N meningitidis infection.